Login
Search
Search
0 Dates
2024
2023
2022
2021
2020
2019
2018
0 Events
CPC 2018
CPC 2019
Curso de Atualização em Medicina Cardiovascular 2019
Reunião Anual Conjunta dos Grupos de Estudo de Cirurgia Cardíaca, Doenças Valvulares e Ecocardiografia da SPC
CPC 2020
CPC 2021
CPC 2022
CPC 2023
CPC 2024
0 Topics
A. Basics
B. Imaging
C. Arrhythmias and Device Therapy
D. Heart Failure
E. Coronary Artery Disease, Acute Coronary Syndromes, Acute Cardiac Care
F. Valvular, Myocardial, Pericardial, Pulmonary, Congenital Heart Disease
G. Aortic Disease, Peripheral Vascular Disease, Stroke
H. Interventional Cardiology and Cardiovascular Surgery
I. Hypertension
J. Preventive Cardiology
K. Cardiovascular Disease In Special Populations
L. Cardiovascular Pharmacology
M. Cardiovascular Nursing
N. E-Cardiology / Digital Health, Public Health, Health Economics, Research Methodology
O. Basic Science
P. Other
0 Themes
01. History of Cardiology
02. Clinical Skills
03. Imaging
04. Arrhythmias, General
05. Atrial Fibrillation
06. Supraventricular Tachycardia (non-AF)
07. Syncope and Bradycardia
08. Ventricular Arrhythmias and Sudden Cardiac Death (SCD)
09. Device Therapy
10. Chronic Heart Failure
11. Acute Heart Failure
12. Coronary Artery Disease (Chronic)
13. Acute Coronary Syndromes
14. Acute Cardiac Care
15. Valvular Heart Disease
16. Infective Endocarditis
17. Myocardial Disease
18. Pericardial Disease
19. Tumors of the Heart
20. Congenital Heart Disease and Pediatric Cardiology
21. Pulmonary Circulation, Pulmonary Embolism, Right Heart Failure
22. Aortic Disease
23. Peripheral Vascular and Cerebrovascular Disease
24. Stroke
25. Interventional Cardiology
26. Cardiovascular Surgery
27. Hypertension
28. Risk Factors and Prevention
29. Rehabilitation and Sports Cardiology
30. Cardiovascular Disease in Special Populations
31. Pharmacology and Pharmacotherapy
32. Cardiovascular Nursing
33. e-Cardiology / Digital Health
34. Public Health and Health Economics
35. Research Methodology
36. Basic Science
37. Miscellanea
0 Resources
Abstract
Slides
Vídeo
Report
CLEAR FILTERS
Shanghai Scoring System for risk stratification in a Portuguese sample of Brugada Syndrome patients
Session:
Sessão Especial – Prémio Melhor Poster Electrónico
Speaker:
Ana Filipa Abreu Cardoso
Congress:
CPC 2022
Topic:
C. Arrhythmias and Device Therapy
Theme:
08. Ventricular Arrhythmias and Sudden Cardiac Death (SCD)
Subtheme:
08.6 Ventricular Arrhythmias and SCD - Clinical
Session Type:
Pósters Electrónicos
FP Number:
---
Authors:
Ana Filipa Cardoso; Geraldo Dias; Tamara Pereira; Mariana Tinoco; Sílvia Ribeiro; Lucy Calvo; Marina Fernandes; Víctor Sanfins; António Lourenço
Abstract
<p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:"Calibri",sans-serif"><strong><span style="background-color:white"><span style="color:#212529">Introduction: </span></span></strong><span style="background-color:white"><span style="color:#212529">Risk stratification is a major challenge in Brugada Syndrome (BS). The </span></span><span style="background-color:white"><span style="color:#212121">Shanghai Brugada Scoring System (SBSS) was proposed as a diagnostic and risk stratification tool for these patients (pts). Our aim was to evaluate the predictive power of SBSS for risk stratification in our population.</span></span></span></span></p> <p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:"Calibri",sans-serif"><strong><span style="background-color:white"><span style="color:#212529">Methods: </span></span></strong><span style="background-color:white"><span style="color:#212529">Single-center retrospective study of BS pts and SCN5A mutation carriers identified thorough family screening. The SBSS was calculated and pts divided in 3 groups: group 1 if ≤3 points; group 2 if 3.5 to 4.5 points; group 3 if ≥5 points. </span></span>Primary endpoint (EP) was a composite of syncope of probable arrhythmic origin, ventricular tachycardia/ventricular fibrillation (VT/VF) and sudden cardiac death (SCD) during the follow-up.</span></span></p> <p style="text-align:justify"><span style="font-size:12pt"><span style="background-color:white"><span style="font-family:"Times New Roman",serif"><strong><span style="font-size:11.0pt"><span style="background-color:white"><span style="font-family:"Calibri",sans-serif"><span style="color:black">Results: </span></span></span></span></strong><span style="font-size:11.0pt"><span style="background-color:white"><span style="font-family:"Calibri",sans-serif"><span style="color:black">We included 166 (86%) BS pts and 28 (14%) </span></span></span></span><span style="font-size:11.0pt"><span style="background-color:white"><span style="font-family:"Calibri",sans-serif"><span style="color:#212529">SCN5A pathogenic mutation </span></span></span></span><span style="font-size:11.0pt"><span style="background-color:white"><span style="font-family:"Calibri",sans-serif"><span style="color:black">carriers (59% males, mean age 51±15 years).</span></span></span></span></span></span></span></p> <p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:"Calibri",sans-serif">At diagnosis, 63 (38%) BS pts had a spontaneous type 1 pattern, including 3 (2%) during febrile illness and the remaining 103 (62%) had drug-induced type 1 pattern. They presented with arrhythmic syncope in 29 (17%) cases; nocturnal agonal respiration in 6 (4%) and aborted SCD in 5 (3%).</span></span></p> <p style="text-align:justify"><span style="font-size:12pt"><span style="background-color:white"><span style="font-family:"Times New Roman",serif"><span style="font-size:11.0pt"><span style="font-family:"Calibri",sans-serif"><span style="color:black">A family history of BS was present in 113 (58%) pts and of sudden cardiac death in 30 (16%) pts. </span></span></span></span></span></span></p> <p style="text-align:justify"><span style="font-size:12pt"><span style="background-color:white"><span style="font-family:"Times New Roman",serif"><span style="font-size:11.0pt"><span style="font-family:"Calibri",sans-serif"><span style="color:black">Genetic testing was done in 149 (77%) pts: 21 pts had a pathogenic and 47 a likely pathogenic SCN5A mutation. Programmed ventricular stimulation<span style="background-color:white"> was performed in 64 (33%) pts and </span></span></span></span><span style="font-size:11.0pt"><span style="font-family:"Calibri",sans-serif"><span style="color:black">VT/VF</span></span></span> <span style="font-size:11.0pt"><span style="background-color:white"><span style="font-family:"Calibri",sans-serif"><span style="color:black">was induced in 17 pts. </span></span></span></span><span style="font-size:11.0pt"><span style="font-family:"Calibri",sans-serif"><span style="color:black">A </span></span></span><span style="font-size:11.0pt"><span style="font-family:"Calibri",sans-serif"><span style="color:black">cardioverter defibrillator</span></span></span><span style="font-size:11.0pt"><span style="font-family:"Calibri",sans-serif"><span style="color:black"> was implanted in 45 (23%) pts.</span></span></span></span></span></span></p> <p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:"Calibri",sans-serif">After application of the SBSS, 40 (21%) pts were categorized as group 1, 95 (49%) pts as group 2 and 59 (30%) pts as group 3. </span></span></p> <p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:"Calibri",sans-serif">During a median follow-up of 27 months (IQR 16-38), 7 patients experienced the primary EP (1 arrhythmic syncope, 6 VT/VF). The incidence rate was of 1.52 events per 100 person-years. Of the pts with the primary EP, 4 had a previous aborted SCD and 3 had a previous syncope of suspected arrhythmic origin. </span></span></p> <p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:"Calibri",sans-serif">The incidence of the primary EP was higher in group 3 (3.49 vs 0 vs 0 events per 100 person-years; log rank =.001).</span></span></p> <p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:"Calibri",sans-serif">The frequency of primary EP rate increased as the SBSS increased (HR: 2.46 per 1-point increase; 95% CI 1.42 to 4.26; p =.002). If data was limited to patients without previous SCD, the score lost its predictive power (HR: 2.51 per 1-point increase; 95% CI: 0.98 to 6.46; p =.056).</span></span></p> <p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:"Calibri",sans-serif"><strong>Conclusion: </strong>In our population, SBSS was a valuable tool for risk stratification and a cutoff of <span style="background-color:white"><span style="color:#212529">≥5 points identified pts with the highest risk of events.</span></span></span></span></p>
Slides
Our mission: To reduce the burden of cardiovascular disease
Visit our site